Literature DB >> 29938558

Characterisation of fused deposition modeling 3D printers for pharmaceutical and medical applications.

Tim Feuerbach1, Stefanie Kock1, Markus Thommes1.   

Abstract

Fused deposition modeling (FDM) is a promising 3D printing technique for the fabrication of personalized drug dosage forms and patient-specific implants. However, there are no market products produced by FDM available at this time. One of the reasons is the lack of a consistent and harmonized approval procedure. In this study, three FDM printers have been characterised with respect to printing parameters relevant for pharmaceutical and medical applications, namely the positioning, hot-end temperature, material residence time, printing velocity and volumetric material flow. The printers are the Ultimaker 2 (UM2), the PRotos v3 (PR3) as well as an in-house developed printer (IDP). The positioning results showed discrepancies between the printers, which are mainly based on different types of drive systems. Due to comparable utilised hot-ends and nozzle geometries, the results for the temperature and residence time distribution measurements were quite similar. The IDP has a high positioning accuracy but is limited with respect to printing velocity, while the achievable material volume flows were different for all printers. The presented characterisation method aims to contribute to the development of a harmonized equipment qualification framework for FDM printers, which could lead to an acceleration and facilitation of an approval procedure for 3D printed products.

Entities:  

Keywords:  3D printing; FDM; fused deposition modeling; positioning; printing velocity; qualification; residence time; temperature; volume flow

Mesh:

Substances:

Year:  2018        PMID: 29938558     DOI: 10.1080/10837450.2018.1492618

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  8 in total

1.  Very-Rapidly Dissolving Printlets of Isoniazid Manufactured by SLS 3D Printing: In Vitro and In Vivo Characterization.

Authors:  Tahir Khuroo; Eman M Mohamed; Sathish Dharani; Canberk Kayalar; Tanil Ozkan; Mathew A Kuttolamadom; Ziyaur Rahman; Mansoor A Khan
Journal:  Mol Pharm       Date:  2022-06-01       Impact factor: 5.364

2.  Design and Characterization of a Screw Extrusion Hot-End for Fused Deposition Modeling.

Authors:  Tim Feuerbach; Markus Thommes
Journal:  Molecules       Date:  2021-01-23       Impact factor: 4.411

Review 3.  Additive Manufacturing Processes in Medical Applications.

Authors:  Mika Salmi
Journal:  Materials (Basel)       Date:  2021-01-03       Impact factor: 3.623

4.  Investigation of Patient-Centric 3D-Printed Orodispersible Films Containing Amorphous Aripiprazole.

Authors:  Ju-Hyun Lee; Chulhun Park; In-Ok Song; Beom-Jin Lee; Chin-Yang Kang; Jun-Bom Park
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-19

5.  The Chronotopic™ System for Pulsatile and Colonic Delivery of Active Molecules in the Era of Precision Medicine: Feasibility by 3D Printing via Fused Deposition Modeling (FDM).

Authors:  Alice Melocchi; Marco Uboldi; Francesco Briatico-Vangosa; Saliha Moutaharrik; Matteo Cerea; Anastasia Foppoli; Alessandra Maroni; Luca Palugan; Lucia Zema; Andrea Gazzaniga
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

Review 6.  Establishing a point-of-care additive manufacturing workflow for clinical use.

Authors:  Georges E Daoud; Dante L Pezzutti; Calvin J Dolatowski; Ricardo L Carrau; Mary Pancake; Edward Herderick; Kyle K VanKoevering
Journal:  J Mater Res       Date:  2021-07-06       Impact factor: 3.089

7.  3D-Printed Solid Dispersion Drug Products.

Authors:  Suet Li Chew; Laura Modica de Mohac; Bahijja Tolulope Raimi-Abraham
Journal:  Pharmaceutics       Date:  2019-12-11       Impact factor: 6.321

8.  Rheological Investigation of Hydroxypropyl Cellulose-Based Filaments for Material Extrusion 3D Printing.

Authors:  Yee Mon Than; Sarisa Suriyarak; Varin Titapiwatanakun
Journal:  Polymers (Basel)       Date:  2022-03-10       Impact factor: 4.329

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.